

Description of the Associate Director for Clinical & Translational Research

Institute for Successful Longevity (ISL)

Purpose

The Institute for Successful Longevity (ISL) is entering a new phase of growth, with expanding collaborations across FSU Health, increasing interdisciplinary research activities, and new opportunities to strengthen clinical and translational aging research. To support these strategic priorities, ISL proposes an Associate Director for Clinical & Translational Research.

Strategic Priorities

The Associate Director for Clinical & Translational Research will provide leadership in the following areas:

- Lead and coordinate the ISL Clinical Research Working Group.
- Advance clinical and translational aging research initiatives across FSU Health.
- The future development, governance, and sustainability of the ISL Volunteer Registry, including evaluating opportunities to strengthen collaboration with FSU Health while preserving the registry's role as a university-wide resource supporting the full spectrum of aging-related research.
- Strengthen participant recruitment pathways for aging-related clinical research.
- Expand interdisciplinary collaboration among ISL faculty affiliates through pilot projects, collaborative publications, and grant development.
- Develop and enhance clinical research training opportunities for undergraduate, graduate, and professional students.
- Coordinate shared research resources and workflows that improve the efficiency and quality of aging-related research.
- Strengthen partnerships among ISL, FSU Health, community organizations, and aging-focused programs across the university.

Alignment with FSU Health and University Priorities

This position directly supports FSU's strategic priorities by:

- Expanding clinical and translational research capacity.
- Strengthening interdisciplinary collaboration across colleges.
- Building sustainable research infrastructure that benefits multiple investigators.
- Supporting workforce development and student training in clinical research.
- Enhancing partnerships with FSU Health and community organizations.
- Increasing competitiveness for externally funded research.

Expected Outcomes (2–3 Years)

The anticipated outcomes of this leadership role include:

- A fully functioning Clinical Research Working Group that supports faculty collaboration.
- Improved participant recruitment infrastructure for aging-related research.
- Increased utilization of the ISL participant registry.
- Expanded student training opportunities in clinical research.
- Increased interdisciplinary grant submissions and collaborative publications.
- Stronger integration between ISL and FSU Health initiatives.
- Enhanced visibility of ISL as a university-wide hub for clinical and translational aging research.

This appointment represents a strategic investment in ISL's research infrastructure rather than an administrative position. By providing dedicated leadership for clinical and translational research initiatives, ISL will be better positioned to:

- Develop sustainable research infrastructure.
- Increase interdisciplinary collaboration.
- Support FSU Health priorities.
- Improve faculty and student engagement.
- Enhance competitiveness for NIH, PCORI, AHRQ, foundations, and other externally funded opportunities.

Ultimately, this role will strengthen ISL's capacity to generate research impact, attract external funding, and advance Florida State University's leadership in aging and longevity research.